Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sphingosylphosphorylcholine (SPC) evokes perinuclear reorganization of keratin 8 (K8) filaments and regulates the viscoelasticity of
metastatic cancer
cells leading to enhanced migration. Few studies have addressed the compounds modulating the viscoelasticity of
metastatic cancer
cells. We studied the effects of sphingosine (SPH), sphingosine 1-phosphate (S1P), FTY720 and FTY720-phosphate (FTY720P) on SPC-induced K8 phosphorylation and reorganization using Western blot and confocal microscopy, and also evaluated the elasticity of PANC-1 cells by atomic force microscopy. FTY720, FTY720P, SPH, and S1P concentration-dependently inhibited SPC-evoked phosphorylation and reorganization of K8, and migration of PANC-1 cells. SPC triggered reduction and narrow distribution of elastic constant K and conversely, FTY720 blocked them. A common upstream regulator of JNK and ERK, protein phosphatase 2A (PP2A) expression was reduced by SPC, but was restored by FTY720 and FTY72P. Butyryl forskolin, a PP2A activator, suppressed SPC-induced K8 phosphorylation and okadaic acid, a PP2A inhibitor, induced K8 phosphorylation. Gene silencing of PP2A also led to K8 phosphorylation, reorganization and migration. We also investigated the involvement of
GPR12
, a high-affinity SPC receptor, in SPC-evoked keratin phosphorylation and reorganization.
GPR12
siRNA suppressed the SPC-triggered phosphorylation and reorganization of K8.
GPR12
overexpression stimulated keratin phosphorylation and reorganization even without SPC. FTY720 and FTY720P suppressed the
GPR12
-induced phosphorylation and reorganization of K8. The collective data indicates that FTY720 and FTY720P suppress SPC-induced phosphorylation and reorganization of K8 in PANC-1 cells by restoring the expression of PP2A via
GPR12
. These findings might be helpful in the development of compounds that modulate the viscoelasticity of
metastatic cancer
cells and various SPC actions.
...
PMID:Novel effects of FTY720 on perinuclear reorganization of keratin network induced by sphingosylphosphorylcholine: Involvement of protein phosphatase 2A and G-protein-coupled receptor-12. 2687 88
GPR12
is a constitutively active, G
s
protein-coupled receptor that currently has no confirmed endogenous ligands.
GPR12
may be involved in physiological processes such as maintenance of oocyte meiotic arrest and brain development, as well as pathological conditions such as
metastatic cancer
. In this study, the potential effects of various classes of cannabinoids on
GPR12
were tested using a cAMP accumulation assay. Our data demonstrate that cannabidiol (CBD), a major non-psychoactive phytocannabinoid, acted as an inverse agonist to inhibit cAMP accumulation stimulated by the constitutively active
GPR12
. Thus,
GPR12
is a novel molecular target for CBD. The structure-activity relationship studies of CBD indicate that both the free hydroxyl and the pentyl side chain are crucial for the effects of CBD on
GPR12
. Furthermore, studies using cholera toxin, which blocks G
s
protein and pertussis toxin, which blocks G
i
protein, revealed that G
s
, but not G
i
is involved in the inverse agonism of CBD on
GPR12
. CBD is a promising novel therapeutic agent for cancer, and
GPR12
has been shown to alter viscoelasticity of
metastatic cancer
cells. Since we have demonstrated that CBD is an inverse agonist for
GPR12
, this provides novel mechanism of action for CBD, and an initial chemical scaffold upon which highly potent and efficacious agents acting on
GPR12
may be developed with the ultimate goal of blocking cancer metastasis.
...
PMID:Cannabidiol, a novel inverse agonist for GPR12. 2888 84